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Background: Thymidylate synthase (TYMS) is an important folate-dependent enzyme in DNA synthesis and an
important target for cancer chemotherapy. High TYMS expression levels in tumors are generally associated with
resistance to 5-fluorouracil (5-FU). The cause of the variability in TYMS expression is still not fully understood,
however, only a small proportion of the TYMS expression can be explained by TYMS genetic polymorphisms.
The purpose of this study is to identify novel microRNAs (miRNAs) which regulate the expression of TYMS and to
determine whether miRNAs binding to the 3′-untranslated region (UTR) of TYMS mRNA affect the proliferation of
HeLa cells treated with 5-FU.
Methods: An in silico search was performed to find potential binding sites of miRNAs in TYMS mRNA. The efficacy
of predicted miRNAs at the 3′-UTR of TYMS mRNA was evaluated using a dual-luciferase reporter assay. TYMS mRNA
and protein expression in HeLa cells was quantified with real-time RT-PCR and Western blotting, respectively. The
effects of miR-433 on cell proliferative activity were determined by WST-8 assay.
Results: The overexpression of miR-433 was associated with significantly decreased reporter activity in the plasmid
containing the 3′-UTR of TYMS mRNA (P < 0.01). The levels of TYMS mRNA and protein in HeLa cells were
significantly decreased by the overexpression of miR-433 (P < 0.05). Furthermore, miR-433 increased inhibition of cell
proliferation in HeLa cells treated with 5-FU at over 2.0 μM.
Conclusion: The results indicate that miR-433 post-transcriptionally regulates the expression of TYMS mRNA and
protein, and increases sensitivity to 5-FU in HeLa cells. This is the first report showing that a miRNA regulating TYMS
expression has a significant impact on sensitivity to 5-FU treatment.
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Thymidylate synthase (TYMS) is an intracellular enzyme
critical for de novo synthesis of thymidine monophosphate
(dTMP), a precursor of the DNA metabolite thymidine tri-
phosphate. Inhibition of TYMS suppresses cellular growth
and leads to cell death. Due to this critical function, TYMS
has been a major target of anti-cancer drugs for the past* Correspondence: ieiri-ttr@umin.ac.jp
†Equal contributors
Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical
Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka 812-8582,
Japan
© 2013 Gotanda et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or50 years [1]. Five-fluorouracil (5-FU), one of several
TYMS inhibitors, is widely used to induce temporary
tumor regression and improve survival, especially for
gastrointestinal cancers [2]. The level of TYMS expression
is known to be related to the response of tumor cells to 5-
FU. Overexpression of TYMS in human colon cancer cells
induced resistance to fluoropyrimidine [3]. In addition,
higher TYMS levels in tumor tissues in cancer patients
were associated with resistance to 5-FU-based chemother-
apy [4-7].
There is considerable interindividual variability in the
clinical response to 5-FU [8]. The 5-FU dose in cancerl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ability in plasma 5-FU levels, up to 100-fold [9], leading to
undesired side effects. This variability may be the major
contributor to toxicity and subsequent treatment failure
[10,11]. Dose management of 5-FU could therefore prove
essential to reducing 5-FU toxicity in patients. Inter-
individual differences in TYMS expression may be respon-
sible for the different clinical responses to 5-FU. Indeed, a
large difference in TYMS mRNA expression was observed
between colorectal tumor and normal tissues [12]. Three
functionally important polymorphisms were identified in
the TYMS gene: (i) rs34743033: a variable number of
28-bp tandem repeat polymorphisms in the promoter re-
gion of the 5′-untranslated enhancer region (UTR) [13];
(ii) rs16430: a 6-bp deletion in the 3′-UTR [14]; and
(iii) rs2853542: a G/C polymorphism in the 5′-UTR en-
hancer region [15]. These polymorphisms showed a sig-
nificant association with poor outcome in 5-FU-treated
patients [16-18]. However, some reports have indicated
that TYMS polymorphisms did not affect the response to
5-FU therapy [12,19].
MicroRNAs (miRNAs) constitute a class of endogenous,
small (19–25 nucleotides), non-coding single-stranded
RNAs, and negatively regulate the translation of multiple
mRNAs by binding to their 3′-UTRs and inhibiting
mRNA translation or breaking down mRNA [20]. It has
been reported that miRNAs play an important role as ei-
ther oncogenes or tumor suppressors, therefore, miRNAs
have been increasingly recognized as useful biomarkers, as
well as therapeutic tools [21,22]. Moreover, recent evi-
dence suggests that miRNA expression influences chemo-
sensitivity in human cancer cells [23-26].
TYMS expression is reported to be regulated by miR-
192 and miR-215 in colorectal cancer cell lines [27]. How-
ever, down regulation of TYMS expression by these
miRNAs did not sensitize cells to 5-FU in colorectal can-
cers. Although high TYMS levels are associated with re-
sistance to 5-FU-based chemotherapy [4-7], no miRNAs
which repress TYMS expression leading to an increase in
sensitivity to 5-FU, have been identified. Interestingly, the
6-bp deletion (rs16430) in the TYMS 3′-UTR is reported
to decrease mRNA stability in vitro and gene expression
in vivo [28]. These results suggest that certain miRNAs,
which target sites proximal to the 6-bp deletion resulting
in lower TYMS expression, exist.
In the current study, we identified a novel miRNA
regulating the expression of TYMS and evaluated its ef-
fect on the proliferation of a human cervical cancer cell
line exposed to 5-FU.
Methods
Cell culture
The human cervical cancer HeLa cell line was obtained
from RIKEN Cell Bank. HeLa cells were cultured inDulbecco’s modified Eagle’s medium (DMEM) (Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 10%
fetal bovine serum (FBS) (Nichirei Biosciences Inc.,
Tokyo, Japan) and incubated at 37°C in 5% carbon
dioxide.
Dual luciferase reporter assays
The full-length 3′-UTR of TYMS gene with and with-
out the 6-bp deletion was amplified from human
genomic DNA using forward and reverse primers (For-
ward 5′- TCATCTAGAACCCAGACCTT -3′, Reverse
5′- CCAATCTAGAATACAGCACA -3′). XbaI (TaKaRa
Inc., Otsu, Japan) restriction sites were created in the
primers for cloning. The products were cloned into the
pGL3 Promoter vector (Promega, Madison, WI, USA)
and named the pGL3 + reference allele or pGL3 + 6 bp
deletion allele. Control luciferase constructs were made
by ligating oligonucleotides containing a perfect com-
plementary sequence to miR-433 into the XbaI site of
the pGL3 Promoter vector (pGL3 + miR-433). HeLa
cells were plated in a 24-well plate at a density of 6.0 ×
104 cells/well and maintained in DMEM with 10% FBS
at 37°C in 5% carbon dioxide. After 24 hours, 380 ng of
reporter plasmid, 20 ng of pRL-TK (Promega), and
negative control precursor miRNA (pre-miR-negative
control) (Applied Biosystems Life Technologies, Carlsbad,
CA, USA) or pre-miR-433 miRNA precursor (pre-
miR-433) (Applied Biosystems) were transfected by
using Lipofectamine 2000 (Invitrogen Life Technologies,
Carlsbad, CA, USA). Reporter assays were performed
at 48 hours post-transfection using the Dual luciferase
assay system (Promega), and normalized for transfection
efficiency by co-transfected Renilla-luciferase.
Transfections of miRNA and small interfering RNA (siRNA)
For Western blotting and quantification of mRNA expres-
sion, 0.75, 1.5, and 3.0 nM of pre-miR-negative control,
pre-miR-433, TYMS siRNA (On-Target plus SMART pool
L-004717-00-0005, Dharmacon, Denver, CO, USA) and
1.0 μL/well Lipofectamine 2000 were mixed with Opti-
MEM I medium (Invitrogen), then introduced into HeLa
cells (1.0 × 105 cells/well) in a 24-well plate.
RNA isolation and quantitative reverse transcription-PCR
analysis of TYMS mRNA
Total RNA from HeLa cells was extracted using the
miRVana PARIS kit (Ambion Life Technologies, Carlsbad,
CA, USA) according to the manufacturer’s instructions at
48 hours after transfection. The RNA samples were then
reverse-transcribed into first strand cDNA with 200 ng of
total RNA, 2.0 μl of 5 × first strand buffer, 2.0 μl of
0.1 mM DTT, 0.5 μl of 500 μg/ml random primer
(Promega), 2.0 μl of 10 mM dNTP mixture and 100
units of SuperScript II RNase H-reverse transcriptase
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42°C for 60 minutes. The mRNA level was measured
with a real-time PCR system (Applied Biosystems). The
following primers were used: for the TYMS mRNA, 5′-
TCTGGAAGGGTGTTTTGGAG-3′ (forward) and 5′-
CCTCCACTGGAAGCCATAAA-3′ (reverse), and for
the β-actin (ACTB) mRNA, 5′-ATGTGGCCGAGGAC
TTTGATT-3′ (forward) and 5′-AGTGGGGTGGCTTT
TAGGATG-3′ (reverse).
Western blotting
HeLa cells were harvested and homogenized with
CelLytic M cell Lysis Reagent (Sigma-Aldrich) and
Protease Inhibitor Cocktail (Sigma-Aldrich) at 48 hours
after transfection. The lysate samples were separated
on 12% SDS-polyacrylamide gels and transferred to
polyvinylidene membranes. The membranes were hy-
bridized with a mouse monoclonal antibody against
human TYMS (Abcam Inc., Cambridge, MA, USA) and
β-actin (Sigma-Aldrich). The immunocomplexes were hy-
bridized with anti-mouse IgG horseradish peroxidase-
linked whole antibody (GE Healthcare, Little Chalfont,
Buckinghamshire, UK). Membranes were washed two
times in PBS-Tween, and specific bands were visualized
using the ECL system (GE Healthcare) according to the
manufacturer’s instructions.
5-FU chemosensitivity
HeLa cells were plated onto a 96-well plate and incu-
bated for 24 hours (4.0 × 103 cells/well). They were then
transfected with Pre-miR-negative control (3.0 nM),
pre-miR-433 (3.0 nM) or TYMS siRNA (3.0 nM) and
treated in 5-FU (Wako, Osaka, Japan) at a final concen-
tration of 0.1, 0.5, 1.0, 2.0, 3.0, 4.0, or 5.0 μM. Cell pro-
liferation was assessed at 120 hours post-transfection
using Cell Counting Kit-8 (Dojindo Laboratories Co.,
Ltd., Kumamoto, Japan) following the manufacturer’s
directions.
Statistical analysis
Statistical analyses were performed with the statistical
software program R version 2.13.1 (R Development Core
Team, 2011). Means for two groups were compared with
an unpaired Student’s t-test (two-tailed). Comparisons of
means for multiple groups against the pre-miR-negative
control transfected cells were analyzed with Dunnett’s
multiple comparison tests. A 5% level of probability was
considered to be significant.
Results
Prediction of miRNAs targeting the 3′-UTR of TYMS mRNA
To identify miRNAs targeting the 3′-UTR of TYMS
mRNA, we used the programs TargetScan (http://www.
targetscan.org) and MiRanda (http://www.microrna.org).MiR-433 was selected as a candidate miRNA binding to
the 3′-UTR of TYMS mRNA based on matching sites
(Figure 1). The 6-bp deletion (rs16430) was located 22 bp
downstream from the predicted miR-433-binding site.
Repressive regulation in the 3’-UTR of TYMS mRNA by
miR-433
The sequence complementary to the miR-433-binding
site and two full-length human TYMS 3′-UTR se-
quences (the wild type or 6-bp deletion) were inserted
downstream of the luciferase reporter gene. We mea-
sured luciferase reporter activity as the effects of repres-
sive post-transcriptional regulation by miR-433. The
luciferase vector with the 6-bp deletion allele showed
significantly lower activity than the wild-type allele in
the negative control miRNA-transfected cells (P < 0.05,
Figure 2). On the other hand, over expression of miR-
433 significantly decreased the reporter activity in the
cells with the 3′-UTR-inserted vectors compared to the
negative control.
Effects of overexpression of miR-433 on TYMS mRNA
levels in HeLa cells
To verify the effect of the overexpression of miR-433 on
TYMS mRNA levels, HeLa cells were temporarily trans-
fected with the pre-miR-negative control, pre-miR-433 or
TYMS siRNA (positive control) and TYMS mRNA levels
were quantitated by real-time RT-PCR analysis using
ACTB for normalization. The overexpression of miR-433
significantly decreased TYMS mRNA levels in a precursor
concentration-dependent manner; reduced by approxi-
mately 50% at 3.0 nM of pre-miR-433 as compared with
the negative control (Figure 3).
Effects of overexpression of miR-433 on TYMS protein
levels in HeLa cells
At all precursor concentrations, siRNA resulted in
TYMS protein deficiency, and miR-433 significantly re-
duced TYMS protein expression compared to the nega-
tive control (Figure 4A, B). Transient transfection of 3.0
nM pre-miR-433 resulted in a 40% reduction in TYMS
protein expression (Figure 4B).
Effects of overexpression of miR-433 on sensitivity to
5-FU in HeLa cells
To evaluate the effect of miR-433 on the sensitivity to 5-
FU treatment, we performed WST-8 assays on HeLa
cells transiently transfected with the pre-miR-negative
control, pre-miR-433 or TYMS siRNA. First, we ana-
lyzed the effects of overexpression of miR-433 and
knock-down of TYMS on cell proliferation without 5-FU
treatment; there was no change in proliferation among
the transfected cells (Figure 5A). TYMS siRNA signifi-
cantly decreased proliferation in cells treated with over
Figure 1 Prediction of miRNA-binding sites in the 3′-UTR of TYMS mRNA. (A) The locations of the 6-bp deletion (indicated as arrow) and
predicted miR-433-binding site in the 3′-UTR of TYMS mRNA. (B) Homology between the 3′-UTR of TYMS mRNA and the predicted target
sequence of miR-433. Numbers indicate mRNA positions.
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trol (Figure 5B). In cells overexpressing miR-433, prolif-
eration was not affected at 5-FU concentrations ranging
from 0.1 to 1.0 μM; however, the decrease in cell prolif-
eration was remarkable over 2.0 μM, and comparable
with that by TYMS siRNA over 3.0 μM. These results
indicate that overexpression of miR-433 sensitizes HeLa
cells to 5-FU treatment.
Discussion and conclusion
In the present study, we tried to identify a novel miRNA
which regulates the expression of TYMS, and evaluate its
effects on 5-FU treatment using HeLa cells. After the
screening of miRNAs targeting the 3′-UTR of TYMSFigure 2 Repressive regulation of luciferase activity including the hum
full-length 3′-UTR of TYMS were transiently introduced with 3.0 nM of pre-m
Luciferase activity was normalized to Renilla luciferase activity. Relative lucif
each precursor. Each column represents the mean ± S.E. for three independ
negative control determined by an unpaired two-sample t-test. †, P < 0.05,
determined by an unpaired two-sample t-test. N.S.: not significant.mRNA, miR-433 was predicted to be located in the 3′-
UTR proximal to the 6-bp deletion (rs16430). Interest-
ingly, the 6-bp deletion has been associated with decreased
mRNA stability and lower gene expression. To demon-
strate that miR-433 directly targets the 3′-UTR with or
without 6-bp deletion allele, we analyzed the luciferase
activity using the vector containing the two alleles. The lu-
ciferase vector with the 6-bp deletion allele showed signifi-
cantly less activity than that with the wild-type vector,
suggesting that the 6-bp deletion in the 3′-UTR was in-
volved in the post-transcriptional regulation of TYMS ex-
pression. Mandola et al. reported that the 6-bp deletion
influenced TYMS mRNA stability [28]. As shown in
Figure 2, overexpression of miR-433 decreased thean 3′-UTR of TYMS by miR-433. Reporter constructs containing the
iR-negative control (NC) or pre-miR-433 (miR-433) into HeLa cells.
erase activity is expressed as a ratio of the Renilla luciferase activity of
ent experiments. *, P < 0.01, compared with the precursor for the
compared with pGL3 + 6-bp deletion for the negative control
Figure 3 Effects of overexpression of miR-433 on TYMS mRNA levels in HeLa cells. Hela cells were transfected with pre-miR-negative
control (NC), pre-miR-433 (miR-433) or TYMS siRNA (0.75, 1.5 and 3.0 nM). The relative TYMS mRNA level was normalized with β-actin. Results
represent the mean ± S.D. for four independent experiments. Relative TYMS mRNA levels were expressed as ratios of the relative TYMS mRNA of
the precursor for the negative control. *, P < 0.05, compared with the negative control determined by Dunnett’s multiple comparison tests.
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pressed TYMS expression, but it was independently ob-
served for the 6-bp deletion allele. Transfection with the
miR-433 precursor significantly decreased TYMS mRNA
and protein levels in a precursor miRNA concentration-
dependent manner (Figures 3 and 4). It was suggested that
miR-433 suppresses the expression of the endogenous
TYMS protein by controlling the stability of TYMSFigure 4 Effects of overexpression of miR-433 on TYMS protein levels
control (NC), pre-miR-433 (miR-433) or TYMS siRNA (0.75, 1.5 and 3.0 nM). T
TYMS protein levels represent the mean ± S.D. for three independent exper
protein levels were expressed as the ratio of the normalized TYMS level to
control determined by Dunnett’s multiple comparison tests.mRNA transcripts. Taking these observations into consid-
eration, miR-433 acts as a repressive regulator, but is not
responsible for the decreased mRNA stability due to the
6-bp deletion.
TYMS is considered the primary target of 5-FU [29,30].
It has been suggested that high TYMS expression is cor-
related with low sensitivity to 5-FU [31,32]. In addition
to TYMS genetic polymorphisms, the contribution ofin HeLa cells. (A) Hela cells were transfected with pre-miR-negative
YMS protein levels were determined by Western blotting. (B) Relative
iments. The TYMS level was normalized with β-actin. Relative TYMS
the pre-miR-negative control. *, P < 0.05, compared with the negative
Figure 5 Effects of miR-433 on the sensitivity to 5-FU in HeLa cells. (A) HeLa cells were transfected with 3.0 nM of pre-miR-negative control
(NC), pre-miR-433 (miR-433) or TYMS siRNA. Cell proliferative activities were determined by WST-8 assay. Each column represents the mean ± S.E.
for three independent experiments. (B) 5-FU chemosensitivity in HeLa cells was measured by WST-8 assay. Each point represents the mean ± S.D.
for three independent experiments. *P < 0.01, compared with the negative control determined by Dunnett’s multiple comparison tests.
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studied. MiR-192/215 decreased TYMS mRNA and pro-
tein levels, but significantly reduced sensitivity to 5-FU by
targeting cell cycle progression [27]. To date, no miRNA
which represses TYMS expression leading to an increase
in sensitivity to 5-FU has been identified. In addition to
TYMS, miR-433 also targets tumor-associated protein
growth factor receptor-bound protein 2 (GRB2) involved
in the molecular pathogenesis of gastric cancer [33]. MiR-
433 expression was reported to be down-regulated in gas-
tric carcinoma [33]. Furthermore, gastric cancer patients
with low expression of miR-433 showed lower survival
rates than patients with high expression [34]. Previous re-
ports indicated that miR-433 acts as an anti-oncogenic
miRNA (anti-oncomir). However, as shown in Figure 5A,
overexpression of miR-433 did not affect cell proliferation
in HeLa cells without 5-FU treatment. Our experimentalconcentration for transfection (at 3.0 nM) was approxi-
mately 7-fold lower than that of the previous report (at
25–50 nM) [33]. It is possible that miR-433 does not act
as an anti-oncomir at lower concentrations.
Conversely, we showed that miR-433 decreased the
proliferation of HeLa cells treated with over 2.0 μM of
5-FU. A concentration of 2.0 μM, approximately 260 μg/
L, is close to the clinical target range of 5-FU; indeed,
450–550 μg/L is recommended for FOLFOX6 in meta-
static colorectal cancer patients with grade 0–1 toxicity
[9]. Hence, miR-433 may improve the efficiency of 5-FU
chemotherapy in keeping with Luo’s report [33] that
overexpression of miR-433 acts as an anti-oncomir.
This study showed that miR-433 had a significant im-
pact on sensitivity to 5-FU by regulating TYMS expres-
sion in vitro. Overexpression of TYMS has been linked
to drug resistance [7]. Since miR-433 regulates TYMS
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TYMS-related drugs (e.g., methotrexate). If this is true,
miR-433 may have potential as an adjuvant therapeutic
to overcome drug resistance.
TYMS, thymidylate synthase; dTMP, thymidine mono-
phosphate; 5-FU, 5-fluorouracil; UTR, untranslated en-
hancer region; miRNAs, microRNAs.
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